RMTI · Rockwell Medical, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | $57.56M | $84.00M | $74.91M | $68.73M | $64.35M | $59.47M |
| Gross Profit | $11.70M | $17.48M | $8.70M | $4.08M | ($2.42M) | $2.73M |
| R&D | $0 | $19.0K | $1.11M | $3.12M | $6.83M | $7.09M |
| SG&A | $14.03M | $14.11M | $12.14M | $15.64M | $15.35M | $16.18M |
| Total Operating Expenses | - | - | - | - | - | - |
| D&A | $2.19M | $2.18M | $1.44M | $576.0K | $668.0K | $834.0K |
| Operating Income | ($4.69M) | $608.0K | ($6.67M) | ($16.78M) | ($30.34M) | ($28.42M) |
| Interest Expense | $1.12M | $1.25M | $2.30M | $1.94M | $2.36M | $1.88M |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | ($5.31M) | ($480.0K) | ($8.44M) | ($18.68M) | ($32.67M) | ($30.89M) |
| EPS - Basic | ($0.15) | ($0.03) | ($0.37) | ($1.89) | ($4.51) | - |
| EPS - Diluted | ($0.15) | ($0.03) | ($0.37) | ($1.89) | ($4.51) | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $10.71M | $15.66M | $8.98M | $10.10M | $13.28M | $48.68M |
| Accounts Receivable | $8.14M | $8.29M | $10.90M | $6.26M | $5.91M | $4.17M |
| Inventory | $3.42M | $5.78M | $5.87M | $5.81M | $4.08M | $3.91M |
| Accounts Payable | $2.00M | $2.87M | $4.52M | $4.05M | $3.74M | $4.16M |
| Current Assets | $38.16M | $37.03M | $28.77M | $35.31M | $35.29M | $69.47M |
| Total Assets | $57.15M | $59.21M | $52.17M | $46.63M | $48.57M | $77.75M |
| Current Liabilities | $9.58M | $14.09M | $16.64M | $17.69M | $20.97M | $12.79M |
| Long-term Debt | $8.83M | $8.47M | $8.29M | $7.55M | $13.19M | $20.95M |
| Total Liabilities | $20.16M | $26.62M | $30.88M | $32.53M | $46.04M | $43.58M |
| Stockholders' Equity | $36.98M | $32.59M | $21.29M | $14.11M | $2.54M | $34.17M |
| Retained Earnings | ($402.99M) | ($397.68M) | ($397.20M) | ($388.76M) | ($370.08M) | ($337.41M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($659.0K) | $4.20M | ($9.41M) | ($17.41M) | ($33.53M) | ($29.64M) |
| Investing Cash Flow | ($8.54M) | ($4.87M) | ($3.04M) | ($2.40M) | $311.0K | $3.21M |
| Financing Cash Flow | $4.25M | $7.35M | $11.34M | $16.63M | ($2.18M) | $63.32M |
| CapEx | $542.0K | $1.01M | - | - | - | - |
| Free Cash Flow | ($1.20M) | $3.19M | - | - | - | - |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - |
| FCF / Net income | 0.23 | -6.65 | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -9.3% | -0.8% | -16.2% | -40.1% | -67.3% | -39.7% |
| Return on equity | -14.4% | -1.5% | -39.6% | -132.4% | -1288.9% | -90.4% |
| Return on invested capital | -8.1% | 1.2% | -17.8% | -61.2% | -152.4% | -40.7% |
| Liquidity | ||||||
| Current ratio | 3.98 | 2.63 | 1.73 | 2.00 | 1.68 | 5.43 |
| Quick ratio | 3.63 | 2.22 | 1.38 | 1.67 | 1.49 | 5.12 |
| Cash ratio | 1.12 | 1.11 | 0.54 | 0.57 | 0.63 | 3.81 |
| Leverage | ||||||
| Debt / Equity | 0.24 | 0.26 | 0.39 | 0.54 | 5.20 | 0.61 |
| Debt / Assets | 0.15 | 0.14 | 0.16 | 0.16 | 0.27 | 0.27 |
| Debt / EBITDA | - | 3.04 | - | - | - | - |
| Interest coverage | -4.2x | 0.5x | -2.9x | -8.7x | -12.9x | -15.1x |
| Equity multiplier | 1.55 | 1.82 | 2.45 | 3.31 | 19.16 | 2.28 |
| Liabilities / Assets | 0.35 | 0.45 | 0.59 | 0.70 | 0.95 | 0.56 |
| Efficiency | ||||||
| Asset turnover | - | - | - | - | - | - |
| Inventory turnover | 16.81 | 14.54 | 12.76 | 11.82 | 15.79 | 15.20 |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | 22d | 25d | 29d | 31d | 23d | 24d |
| Days payable outstanding | 13d | 12d | 22d | 22d | 21d | 26d |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | 0.8x | 1.9x | 2.1x | 0.7x | 134.5x | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | 20.1x | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | -33.1% | 100.9% | 113.5% | - | - | -4.0% |
| Operating income growth (YoY) | - | - | 60.3% | 44.7% | -6.7% | 17.7% |
| Net income growth (YoY) | -1007.1% | 94.3% | 54.8% | 42.8% | -5.8% | 9.5% |
| EPS growth (YoY) | -400.0% | 91.9% | 80.4% | 58.1% | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | 13.5% | 53.1% | 50.9% | 456.4% | -92.6% | 68.2% |
Stability scores
Piotroski F-score
FY 2025 · 9-point quality
2/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- ✗Long-term debt decreased
- ✓Current ratio improved
- ✗No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing ROCKWELL MEDICAL against the 5 most active filers in the same SIC group.